Bristol Myers Squibb (BMY) ended the recent trading session at $56.29, demonstrating a -0.16% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

Analysts at Leerink Partnrs boosted their Q4 2024 EPS estimates for Bristol-Myers Squibb in a report released on Sunday, ...

Of the more than 7.7 million people estimated to be living with sickle cell disease, more than 80% were in sub-Saharan Africa ...

Bristol Myers Squibb Co. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety coupled to a DNA-binding protein Ikaros (IKZF1 ...

The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.

Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $55.74 which represents a slight increase of $0.38 or 0.69% from the prior close of $55.36. The stock opened at $55.5 and ...

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...

Bristol Myers (BMY) new psychiatric drug Cobenfy is effective in treating schizophrenia without “the serious side effects’ of other older ...

The stock's rise snapped a three-day losing streak.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...